Genetic syndromes as potential targets for chemoprevention of colorectal neoplasia.
Colorectal cancer is the second leading cause of cancer death in the United States (Landis et al. [1998] CA 48:6-29) and is the most common cancer in Israel (Muir et al. [1997] International Agency for Research on Cancer, Lyon, France). In the United States, it is estimated that 130,000 individuals will be diagnosed with colorectal cancer in 1999 and that 57,000 individuals will die from this disease. In Israel, approximately 2,000 individuals are diagnosed with colorectal cancer each year (Landis et al. [1998] CA 48:6-29). The incidence rate varies considerably in different population groups, viz. 21.1/100,000 among Jews born in Europe or North America, 19.3/100,000 in Jews born in Israel, 12.1/100,000 among Jews born in Africa or Asia (Muir et al. [1997] International Agency for Research on Cancer, Lyon, France).
Levin
B
B
Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
D018256:Adenomatous Polyps / Q000453:epidemiology / Q000235:genetics; D000367:Age Factors; D014408:Biomarkers, Tumor; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism / Q000517:prevention & control*; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000453:epidemiology / Q000235:genetics; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology; D012307:Risk Factors
D014408:Biomarkers, Tumor; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases